245 related articles for article (PubMed ID: 33101274)
1. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
Front Immunol; 2020; 11():559152. PubMed ID: 33101274
[TBL] [Abstract][Full Text] [Related]
2. Targeting of the WT1
Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU
Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368
[TBL] [Abstract][Full Text] [Related]
3. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.
de Haar C; Plantinga M; Blokland NJ; van Til NP; Flinsenberg TW; Van Tendeloo VF; Smits EL; Boon L; Spel L; Boes M; Boelens JJ; Nierkens S
Oncoimmunology; 2015 Nov; 4(11):e1023973. PubMed ID: 26451309
[TBL] [Abstract][Full Text] [Related]
4. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
5. High expression of Fas ligand on cord blood dendritic cells: a possible immunoregulatory mechanism after cord blood transplantation.
Naderi N; Moazzeni SM; Pourfathollah AA; Alimoghaddam K
Transplant Proc; 2011 Dec; 43(10):3913-9. PubMed ID: 22172872
[TBL] [Abstract][Full Text] [Related]
6. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
Van Tendeloo VF; Van de Velde A; Van Driessche A; Cools N; Anguille S; Ladell K; Gostick E; Vermeulen K; Pieters K; Nijs G; Stein B; Smits EL; Schroyens WA; Gadisseur AP; Vrelust I; Jorens PG; Goossens H; de Vries IJ; Price DA; Oji Y; Oka Y; Sugiyama H; Berneman ZN
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13824-9. PubMed ID: 20631300
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.
Anguille S; Van de Velde AL; Smits EL; Van Tendeloo VF; Juliusson G; Cools N; Nijs G; Stein B; Lion E; Van Driessche A; Vandenbosch I; Verlinden A; Gadisseur AP; Schroyens WA; Muylle L; Vermeulen K; Maes MB; Deiteren K; Malfait R; Gostick E; Lammens M; Couttenye MM; Jorens P; Goossens H; Price DA; Ladell K; Oka Y; Fujiki F; Oji Y; Sugiyama H; Berneman ZN
Blood; 2017 Oct; 130(15):1713-1721. PubMed ID: 28830889
[TBL] [Abstract][Full Text] [Related]
8. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
9. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.
Willemen Y; Van den Bergh JM; Bonte SM; Anguille S; Heirman C; Stein BM; Goossens H; Kerre T; Thielemans K; Peeters M; Van Tendeloo VF; Smits EL; Berneman ZN
Oncotarget; 2016 Nov; 7(45):73960-73970. PubMed ID: 27659531
[TBL] [Abstract][Full Text] [Related]
10. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
11. Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine.
Koukoulias K; Papadopoulou A; Kouimtzidis A; Papayanni PG; Papaloizou A; Sotiropoulos D; Yiangou M; Costeas P; Anagnostopoulos A; Yannaki E; Kaloyannidis P
Br J Haematol; 2021 Jul; 194(1):158-167. PubMed ID: 34036576
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
[TBL] [Abstract][Full Text] [Related]
13. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.
Ito Z; Kan S; Bito T; Horiuchi S; Akasu T; Yoshida S; Kajihara M; Hokari A; Saruta M; Yoshida N; Kobayashi M; Ohkusa T; Shimodaira S; Okamoto M; Sugiyama H; Koido S
Oncology; 2019; 97(3):135-148. PubMed ID: 31216557
[TBL] [Abstract][Full Text] [Related]
14. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
[TBL] [Abstract][Full Text] [Related]
15. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
[TBL] [Abstract][Full Text] [Related]
16. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
Kitawaki T; Kadowaki N; Kondo T; Ishikawa T; Ichinohe T; Teramukai S; Fukushima M; Kasai Y; Maekawa T; Uchiyama T
Am J Hematol; 2008 Apr; 83(4):315-7. PubMed ID: 18081032
[TBL] [Abstract][Full Text] [Related]
17. Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
Nakae Y; Oka Y; Fujiki F; Morimoto S; Kamiya T; Takashima S; Nakata J; Nishida S; Nakajima H; Hosen N; Tsuboi A; Kyo T; Oji Y; Mizuguchi K; Kumanogoh A; Sugiyama H
Cancer Immunol Immunother; 2015 Jul; 64(7):791-804. PubMed ID: 25835542
[TBL] [Abstract][Full Text] [Related]
18. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
[TBL] [Abstract][Full Text] [Related]
19. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.
Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H
J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655
[TBL] [Abstract][Full Text] [Related]
20. [In vitro anti-leukemia activity of cord blood original cytotoxic T lymphocytes].
Zeng LJ; Tan H
Ai Zheng; 2005 Apr; 24(4):419-24. PubMed ID: 15820063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
